clofibrate has been researched along with pravastatin in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 8 (32.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Fent, K; Popovic, M; Smital, T; Zaja, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Itakura, H | 1 |
| Shepherd, J | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Alonso-Galicia, M; Roman, RJ; Wilson, TW | 1 |
| Aragane, K; Kitamine, T; Kusunoki, J; Ohnishi, H; Yamaura, T | 1 |
| Pritzker, LB | 1 |
| Haffner, SM | 1 |
| Steiner, G | 1 |
| Hampson, JP; Harvey, JN; Rizvi, K | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Gillies, C; Manktelow, B; Potter, JF | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Tomiyama, N; Yasuda, N | 1 |
8 review(s) available for clofibrate and pravastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.
Topics: Clinical Trials as Topic; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Do lipid lowering drugs reduce the risk of coronary heart disease?
Topics: Angiography; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Coronary Artery Disease; Coronary Disease; Europe; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Survival Rate | 1998 |
The use of fibrates and of statins in preventing atherosclerosis in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Clofibrate; Diabetes Complications; Diabetes Mellitus; Humans; Hypolipidemic Agents; Pravastatin; Simvastatin | 2001 |
Do lipid-lowering drugs cause erectile dysfunction? A systematic review.
Topics: Adult; Clofibrate; Erectile Dysfunction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin | 2002 |
Interventions in the management of serum lipids for preventing stroke recurrence.
Topics: Cardiovascular Diseases; Clofibrate; Estrogens, Conjugated (USP); Humans; Hypolipidemic Agents; Pravastatin; Recurrence; Stroke | 2002 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
1 trial(s) available for clofibrate and pravastatin
| Article | Year |
|---|---|
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
16 other study(ies) available for clofibrate and pravastatin
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Treatment of hyperlipidemia].
Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dietary Fiber; Energy Intake; Female; Humans; Hyperlipidemias; Male; Niceritrol; Pravastatin; Probucol | 1992 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Diet, Sodium-Restricted; Enzyme Induction; Female; Fenofibrate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Kidney; Kidney Glomerulus; Male; Mixed Function Oxygenases; Pravastatin; Proteinuria; Rats; Rats, Inbred Strains; Sodium, Dietary; Triglycerides; Weight Gain | 1998 |
[Effect of F-1394, a potent and selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells].
Topics: Anilides; Anticholesteremic Agents; Caco-2 Cells; Cholesterol; Cholesterol Esters; Clofibrate; Cyclohexanes; Dioxanes; Esterification; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Phenylurea Compounds; Pravastatin; Probucol; Simvastatin; Sterol O-Acyltransferase | 1997 |
Secondary prevention of coronary heart disease: the role of fibric acids.
Topics: Anticholesteremic Agents; Clofibrate; Coronary Disease; Humans; Pravastatin | 2000 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome | 1999 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Caspase 3; Cell Line; Clofibrate; DNA Fragmentation; Drug Synergism; Enzyme Activation; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Pravastatin; Pyridines; Pyrroles | 2007 |